Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7812041 | 0.96 | EPHX1 (0.53) | EPHX1DPP4ALDH1A1ALOX15TSHR | |
| SCHEMBL8495444 | 0.94 | EPHX1 (0.56) | EPHX1DPP4ALDH1A1ALOX15TSHR | |
| SCHEMBL7815595 | 0.91 | EPHX1 (0.42) | EPHX1DPP4SMN1; SMN2LMNA | |
| SCHEMBL23437012 | 0.91 | EPHX1 (0.42) | EPHX1DPP4ALDH1A1ALOX15TSHR | |
| SCHEMBL25270786 | 0.88 | EPHX1 (0.40) | EPHX1DPP4ALDH1A1ALOX15TSHR | |
| SCHEMBL16689636 | 0.86 | EPHX1 (0.41) | EPHX1DPP4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL20398852 | 0.86 | DPP4 (0.38) | EPHX1DPP4L3MBTL1 | |
| SCHEMBL16505644 | 0.84 | EPHX1 (0.40) | EPHX1DPP4SMN1; SMN2L3MBTL1 | |
| SCHEMBL25276302 | 0.84 | EPHX1 (0.38) | EPHX1DPP4SMN1; SMN2 | |
| SCHEMBL25270841 | 0.83 | EPHX1 (0.39) | EPHX1DPP4ALDH1A1ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114641466-A | Sulfonylurea derivatives and use thereof | 诺瑟拉有限公司 | 2022-06-17 | — | — | CN | disclosed |
| CN-104136411-A | therapeutically active compounds and methods of use thereof | AGIOS PHARMACEUTICALS INC | 2014-11-05 | — | — | CN | disclosed |
| CN-104024258-A | Pyrrolopyrazine kinase inhibitors | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | disclosed |
| CN-103814030-A | Pyrrolopyrimidine and purine derivatives | PFIZER | 2014-05-21 | — | — | CN | disclosed |
| CN-103153978-A | Compounds and methods for the treatment or prevention of flaviviridae viral infections | VERTEX PHARMA | 2013-06-12 | — | — | CN | disclosed |
| CN-102971286-A | New cathepsin S protease inhibitors for the treatment of e.g. autoimmune disorders, allergy and chronic pain conditions | MEDIVIR UK LTD | 2013-03-13 | — | — | CN | disclosed |
| CN-102858751-A | Cysteine protease inhibitors | MEDIVIR UK LTD | 2013-01-02 | — | — | CN | disclosed |
| CN-102834383-A | Cysteine protease inhibitors | MEDIVIR UK LTD | 2012-12-19 | — | — | CN | disclosed |
| CN-102791708-A | Inhibitors of akt activity | ALMAC DISCOVERY LTD | 2012-11-21 | — | — | CN | disclosed |
| US-RE42375-E1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-RE42375-E1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2007-03-15 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060510-A1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, HPN | EPHX1 655/4885DPP4 6/4885ALDH1A1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.